Incidence, Risk Factors and Outcome of Empyema Following Pneumonectomy for Non Small Cell Lung Cancer (NSCLC)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 600
- Locations
- 1
- Primary Endpoint
- Overall survival
Study Overview
Brief Summary
Empyema following pneumonectomy for Non Small Cell Lung Cancer (NSCLC) is a known problem that occurs in about 2% of pneumonectomy patients.
Detailed Description
The development of an empyema following pneumonectomy is a devastating complication, especially if associated with an underlying fistula. Whilst the perioperative mortality of pneumonectomy overall is now less than 5%, this rises to around 25% when complicated by empyema, and about 50% when associated with fistula. In addition, there is the morbidity and social cost of long-term drainage, chronic sepsis and often multiple operations.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Pneumonectomy for NSCLC
Exclusion Criteria
- •Pneumonectomy for other reasons (infectious pathology, trauma, mesothelioma, ...)
Outcomes
Primary Outcomes
Overall survival
Time Frame: 5 years from surgery
overall 5-year survival after empyema following pneumonectomy
Secondary Outcomes
- incidence rate(1 and 5 years from surgery)
Investigators
Johnny Moons
Datamanager Thoracic Surgery
University Hospital, Gasthuisberg